BRD4 and mantle cell lymphoma: We have demonstrated that dual and triple action TP-scaffold compounds show promising results as anti-cancer agents [27–29], and the first generation of BTK/PI3K/BRD4 inhibitors, such as SRX3262, was cytotoxic to MCL cells [30].